On June 18th, we hosted the Annual General Meeting for the fiscal year 2023. We are grateful for the support of our investors, board members, and coworkers. It was a wonderful gathering to wrap up 2023, showcase the milestones we achieved and share future goals and objectives.
The highlight of 2023 was the development and launch of our second product, NeoMega36. From idea to launched product within just one year. This is a significant achievement we take great pride in, and we are now exploring new projects to expand our product portfolio.
Neobiomics continues to grow each year, expanding both the business and team. We welcomed Sales Manager Carla Martino in the beginning of 2023 and initiated the recruitment of a new CEO. In 2024, we welcomed Emma Höglund as the new CEO of Neobiomics. Our team has successfully onboarded over 180 customers to date in 20+ countries. We are striving to expand further to make our products available in new territories, for the benefit of patients and their families. We aim to strengthen our brand through additional collaborations with trusted distributors in the coming years.
Following a productive meeting, the Neobiomics team celebrated at a rooftop bar overlooking the city of Stockholm. It was fantastic to have the entire team gathered to celebrate our accomplishments.
